• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Students, Activists, Swarm To Demand UCLA Drop Indian High Court Patent Claim

06/09/2018 by David Branigan, Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Thousands of students have urged a major research university in the United States to drop a patent claim in India related to an important cancer medicine, with the aim of making affordable versions available.

UCLA campus mascot is rather unwelcoming

Universities Allied for Essential Medicines (UAEM) delivered 3,500 signatures this week to the University of California, Los Angeles, (UCLA) President Janet Napolitano, urging the university to drop its patent claim filed in the Indian High Court for enzalutamide, a prostate cancer medicine, according to a UAEM press release [pdf].

Enzalutamide is a “publicly-funded cancer drug discovered on the university campus,” but “the patent filed with the Indian High Court in Delhi by UCLA [was] on behalf of the pharmaceutical corporations,” according to the press release.

The drug, marketed by Pfizer and Astellas as Xtandi, “is currently sold in the U.S. for as much as $150,000 per annual treatment,” according to the release. The patent claim “would prevent generic production of the drug in India, preventing access for millions given that the country is known for developing and exporting most of the world’s generic medications,” it said.

The Indian High Court is expected to make a decision on the patent claim in the coming weeks, which according to the press release “will have great ramifications for the global health community and inform future patent claims as well as licensing patterns.”

Activists hope that the signatures will push Napolitano to start prioritizing affordable cancer medicines at the “flagship” university this year, according to the release.

“We are greatly disappointed that Sherry Lansing, David Geffen and Janet Napolitano are hell-bent on cutting off the possibility of low cost generic versions of enzalutamide in developing countries where billions live. The University of California has declined to provide a rationale for why it is compelled to pursue patent protection in India, after the patent was rejected by the India patent office. The prices in developing countries by Astellas are exorbitant and the decision by the board of regents to support this litigation are a stain on the character of each member,” Jamie Love, director of Knowledge Ecology International, said in the release.

 

Image Credits: UCLA

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

David Branigan may be reached at davidbranigan@gmail.com.

Creative Commons License"Students, Activists, Swarm To Demand UCLA Drop Indian High Court Patent Claim" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, English, Finance, Health & IP, IP Law, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy

Trackbacks

  1. SpicyIP Weekly Review (September 3-9) | SpicyIP says:
    09/09/2018 at 8:13 pm

    […] Students, Activists, Swarm To Demand UCLA Drop Indian High Court Patent Claim […]

    Reply
  2. UCLA Students Protest University Patent Claim On Prostrate Cancer Treatment – Health Policy Watch says:
    13/03/2019 at 5:59 pm

    […] to drop its claim altogether. Students last year met with UCLA administrators and delivered a petition with 3500 signatures to UC President Janet Napolitano as part of their […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.